BGNE250117C185000
- 6.40
- 0.000.00%
BeiGene Newsroom
With 45% Institutional Ownership, BeiGene, Ltd. (NASDAQ:BGNE) Is a Favorite Amongst the Big Guns
US stock movement | BEIGENE pre-market up about 1.6%, plans to change its US stock code, reaffirms commitment to providing innovative cancer drugs.
On December 24, Glonghui reported that BEIGENE (BGNE.US) increased by about 1.6% pre-market, reaching $180.53. In news, BEIGENE announced that to reflect the company's steadfast commitment to providing innovative cancer drugs globally, the stock code for its American Depositary Shares listed on Nasdaq will change from "BGNE" to "ONC," effective January 2, 2025. (Glonghui)
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
CCTV interprets a more proactive fiscal policy: next year's fiscal funding will be allocated earlier, faster, and in greater amounts.
Next year, a more proactive fiscal policy will be implemented. What measures will the Ministry of Finance take? Where will the fiscal funds be focused? What impact will this have on our lives?
BEIGENE (06160.HK) Nasdaq stock code changed to "ONC".
BEIGENE (06160.HK)(BGNE.US) announced that in order to reflect the company's firm commitment to providing innovative oncology drugs globally, the stock code for the American depositary shares traded on Nasdaq will change from "BGNE" to "ONC," effective January 2, 2025.
BeiGene Ltd Updates Nasdaq Ticker Symbol
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Express News | Beigene to Change Nasdaq Ticker Symbol to “Onc” on January 2; Present at 43Rd Annual J.P. Morgan Healthcare Conference
Express News | BEIGENE: The company's Nasdaq stock code will change from "BGNE" to "ONC."
Institutions reiterated a "Buy" rating for BEIGENE (06160), being bullish on its strong oncology drug research and development pipeline.
Recently, BEIGENE (06160) held an investor conference call to introduce important data presentations at the USA Hematology Association (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Subsequently, TD Cowen Inc 7.75% Senior Notes Due 15/06/33 Usd25 reaffirmed BEIGENE's "Buy" rating and maintained a Target Price of $260.00, which aligns with the consensus of many Analysts who believe that this Stocks has potential for upward movement.
Bank of America Merrill Lynch has lowered the Target Price for Shanghai Pharmaceuticals (01093.HK) to 4.6 yuan and raised the Target Price for INNOVENT BIO (01801.HK) to 56.4 yuan.
Merrill Lynch Securities released a Research Report stating that CSPC PHARMA (01093.HK) and BEIGENE (06160.HK) have reached a global exclusive licensing agreement for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor SYH2039 and subsequent development. Taking into account the aforementioned collaboration and the recent bidding results of the tenth batch of national organization pharmaceutical centralized procurement, the revenue forecasts for CSPC PHARMA for 2024 to 2026 have been adjusted down by 0.8%, up by 1.7%, and down by 1.7%, respectively, while the earnings per share forecasts have been adjusted down by 0.9%, up by 10.5%, and down by 1.9%. Considering CSPC PHARMA's core product Enbrel.
UBS Group: The price reduction of the tenth round of collective procurement of Pharmaceuticals exceeded expectations, showing a cautious attitude towards the China generic drug market.
UBS Group released a research report stating that the tenth batch of national Pharmaceutical procurement in the mainland involves 62 types of Pharmaceuticals, with 385 products eligible for selection. Although the government has not disclosed the price reduction situation, according to Statistics, this time the reduction exceeds expectations, reaching 80% to 96%, and it is believed to be the largest reduction in history. The results of the Pharmaceutical procurement will be comprehensively implemented nationwide starting from April next year and will remain effective until the end of 2027. Overall, UBS Group believes that the results of the tenth batch of national Pharmaceutical procurement reflect China's tightening of the basic Medical Insurance Fund, and the government has also increased support for new drugs. Looking ahead, the bank holds a cautious attitude towards the prospects of China's generic drug market, and also anticipates.
US stocks movement | BEIGENE continues to rise 0.84% in pre-market trading with several Institutions giving it a Buy rating.
Gelonghui, December 18 | Yesterday, BEIGENE (BGNE.US) closed up 1.55%, and in Pre-Market Trading today, it continued to rise by 0.84%, reaching $180.56. Analyst Kelly Shi from Jefferies Group maintains a Buy rating for BEIGENE and keeps the Target Price at $286. TD Cowen Inc 7.75% Senior Notes Due 15/06/33 Usd25 analyst Yaron Werber also maintains a Buy rating for BEIGENE with a Target Price of $260. (Gelonghui)
Quick look at the Hong Kong market | All three major Indices closed higher, the Science and Technology Index rose nearly 2%; technology, Autos, and Biotechnology stocks climbed, with Li Auto rising over 5%, and Xiaomi Group and WUXI BIO rising nearly 3%.
Many Network Technology stocks are rising, XIAOMI-W is up 2.84%, Baidu Group-SW is up 1.74%; Semiconductor stocks are all rising, HG SEMI is up 7.64%, BEKE is down 2.78%; Autos stocks are climbing, LEAPMOTOR is up 6.42%, BRILLIANCE CHI is up 6.29%;
Express News | The USA Biological Security Act was not included in the CR bill.
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials